Core Viewpoint - The company plans to acquire a 51% stake in Chengdu Mite Aviation Manufacturing Co., Ltd. for 194 million yuan, which will make Mite Aviation a subsidiary of the company [1] Group 1: Acquisition Details - The acquisition price is set at 194 million yuan [1] - The transaction involves signing a share transfer agreement with the counterpart [1] - Upon completion, Mite Aviation will become a controlling subsidiary of the company [1] Group 2: Strategic Benefits - This acquisition is expected to enhance the company's participation in the aerospace defense equipment sector [1] - Mite Aviation's capabilities in aerospace component R&D, design, and manufacturing align well with the company's precision manufacturing and management strengths [1] - The company aims to enter a new business area and cultivate profit growth points through this acquisition [1] Group 3: Operational Efficiency - The company plans to improve overall operational efficiency and core competitiveness through subsequent resource integration and empowerment [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. from Weigao Co., Weihe Shengxi, and Weihai Ruiming [1] Group 1: Transaction Details - The company will resume trading on November 3, 2025 [1] - The acquisition aims to integrate the target company's technological accumulation and product layout, expanding the product line into the pharmaceutical packaging sector [1] Group 2: Strategic Benefits - Post-transaction, the company can leverage its hollow fiber filtration technology alongside the target company's extensive customer resources in biopharmaceuticals [1] - This collaboration is expected to enhance both parties' product technology reserves and sales channels, focusing on the biopharmaceutical filter business and expanding into the upstream biopharmaceutical market [1]